ES2132644T3 - Metodo para reproducir in vitro la actividad proteolitica de la proteasa ns3 del virus de la hepatitis c (vhc). - Google Patents
Metodo para reproducir in vitro la actividad proteolitica de la proteasa ns3 del virus de la hepatitis c (vhc).Info
- Publication number
- ES2132644T3 ES2132644T3 ES95909937T ES95909937T ES2132644T3 ES 2132644 T3 ES2132644 T3 ES 2132644T3 ES 95909937 T ES95909937 T ES 95909937T ES 95909937 T ES95909937 T ES 95909937T ES 2132644 T3 ES2132644 T3 ES 2132644T3
- Authority
- ES
- Spain
- Prior art keywords
- ns4a
- hcv
- precursor
- vitro
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000000338 in vitro Methods 0.000 title abstract 3
- 108091005804 Peptidases Proteins 0.000 title abstract 2
- 239000004365 Protease Substances 0.000 title abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 2
- 230000002797 proteolythic effect Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 101800001020 Non-structural protein 4A Proteins 0.000 abstract 8
- 230000000694 effects Effects 0.000 abstract 4
- 239000002243 precursor Substances 0.000 abstract 4
- 102000012479 Serine Proteases Human genes 0.000 abstract 3
- 108010022999 Serine Proteases Proteins 0.000 abstract 3
- 230000002255 enzymatic effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ESTE ES UN METODO PARA REPRODUCIR IN VITRO LA ACTIVIDAD DE PROTEASA DE SERINA ASOCIADA CON LA PROTEINA NS3 DEL VHC. EL METODO INCLUYE EL USO TANTO DE LAS SECUENCIAS CONTENIDAS EN LA NS3 COMO LAS CONTENIDAS EN LA NS4A. ESTE METODO APROVECHA LA CAPACIDAD DE LA PROTEINA NS4A DEL VHC O DE LAS SECUENCIAS QUE CONTIENE PARA ACTUAR COMO UN COFACTOR DE LA ACTIVIDAD DE LA PROTEASA DE SERINA O, DE FORMA MAS GENERAL, DE LAS ACTIVIDADES ENZIMATICAS ASOCIADAS CON NS3. LA ACTIVIDAD OPTIMA DE PROTEASA DE SERINA SE OBTIENE CUANDO NS4A ESTA PRESENTE EN UN RADIO MOLAR DE AL MENOS 1:1, CON NS3. NS3 Y NS4A TAMBIEN PUEDEN INCORPORARSE EN LA MEZCLA DE REACCION EN FORMA DEL PRECURSOR NS3-NS4A, YA QUE ESTE PRECURSOR GENERARA, A TRAVES DE UN MECANISMO AUTOPROTEOLITICO, CANTIDADES EQUIMOLARES DE NS3 Y NS4A. TAMBIEN ES POSIBLE MUTAR EL SITIO DE RUPTURA ENTRE NS3 Y NS4A EN UN PRECURSOR PARA QUE NS4A SE MANTENGA UNIDA COVALENTEMENTE A NS3. LAS SECUENCIAS QUE NO TIENEN INFLUENCIA SOBRE LA ACTIVIDAD PROTEOLITICA DE NS3 PUEDEN ELIMINARSE A CONTINUACION DE DICHO PRECURSOR NO PROTEOLIZABLE. ESTA INVENCION TAMBIEN SE RELACIONA CON UNA COMPOSICION DE MATERIA QUE INCLUYE LAS SECUENCIAS CONTENIDAS EN NS3 Y NS4A Y CON EL USO DE ESTAS COMPOSICIONES PARA ESTABLECER UNA PRUEBA ENZIMATICA CAPAZ DE SELECCIONAR, CON FINES TERAPEUTICOS, COMPUESTOS QUE INHIBAN LA ACTIVIDAD ENZIMATICA ASOCIADA CON NS3. LA FIGURA MUESTRA LOS PLASMIDOS VECTORES UTILIZADOS EN EL METODO PARA ACTIVAR A LA PROTEASA DE NS3 DEL VHC EN CELULAS CULTIVADAS E IN VITRO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM940092A IT1272179B (it) | 1994-02-23 | 1994-02-23 | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2132644T3 true ES2132644T3 (es) | 1999-08-16 |
Family
ID=11402272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95909937T Expired - Lifetime ES2132644T3 (es) | 1994-02-23 | 1995-02-14 | Metodo para reproducir in vitro la actividad proteolitica de la proteasa ns3 del virus de la hepatitis c (vhc). |
Country Status (15)
Country | Link |
---|---|
US (1) | US5739002A (es) |
EP (1) | EP0746333B1 (es) |
JP (1) | JP3280384B2 (es) |
AT (1) | ATE179611T1 (es) |
AU (1) | AU691259B2 (es) |
BR (1) | BR9506931A (es) |
CA (1) | CA2182521C (es) |
DE (1) | DE69509504T2 (es) |
DK (1) | DK0746333T3 (es) |
ES (1) | ES2132644T3 (es) |
GR (1) | GR3030166T3 (es) |
HK (1) | HK1010988A1 (es) |
IT (1) | IT1272179B (es) |
RU (1) | RU2149185C1 (es) |
WO (1) | WO1995022985A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767233A (en) * | 1995-05-12 | 1998-06-16 | Schering Corporation | Soluble cleavable substrates of the hepatitis C virus protease |
US5843752A (en) * | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
IT1278077B1 (it) * | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
JPH11513890A (ja) * | 1996-05-10 | 1999-11-30 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの合成インヒビター |
US5990276A (en) * | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
EP1364961B1 (en) * | 1996-09-12 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained |
US6153579A (en) * | 1996-09-12 | 2000-11-28 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
US5861297A (en) * | 1996-09-27 | 1999-01-19 | Merck & Co., Inc. | Detergent-free hepatitis C protease |
AU4904397A (en) * | 1996-10-17 | 1998-05-11 | Chiron Corporation | Protease regulator screening assay |
WO1998037180A2 (en) * | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
US6251583B1 (en) | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
US6280940B1 (en) | 1998-08-05 | 2001-08-28 | Agouron Pharmaceuticals, Inc. | Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
WO2000040707A1 (en) * | 1999-01-08 | 2000-07-13 | Bristol-Myers Squibb Co. | Modified forms of hepatitis c virus ns3 protease |
CA2376965A1 (en) * | 1999-07-07 | 2001-01-11 | Timothy Patrick Forsyth | Peptide boronic acid inhibitors of hepatitis c virus protease |
WO2001038538A1 (en) * | 1999-11-23 | 2001-05-31 | Viropharma Incorporated | Polymerase compositions and methods of use thereof |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
ATE461207T1 (de) * | 2000-07-21 | 2010-04-15 | Schering Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
AR029851A1 (es) * | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
WO2002008187A1 (en) * | 2000-07-21 | 2002-01-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
EP1423522A2 (en) * | 2001-01-23 | 2004-06-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hepatitis c virus replicons and replicon enhanced cells |
WO2003026589A2 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
ATE467680T1 (de) | 2001-10-11 | 2010-05-15 | Merck Sharp & Dohme | Hepatitis-c-virus-impfstoff |
DE60236364D1 (en) | 2001-10-11 | 2010-06-24 | Angeletti P Ist Richerche Bio | Hepatitis-c-virus-impfstoff |
DE60326831D1 (en) | 2002-04-16 | 2009-05-07 | Merck & Co Inc | Hepatitis-c-virus-testsysteme |
CA2514918C (en) * | 2003-02-13 | 2012-07-03 | Merck & Co., Inc. | Method to confer cell culture replication activity to different hepatitis c virus isolates |
US7414031B2 (en) * | 2004-11-22 | 2008-08-19 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
WO2006093986A1 (en) * | 2005-02-28 | 2006-09-08 | Genelabs Technologies, Inc. | Tricyclic-nucleoside prodrugs for treating viral infections |
US7834145B2 (en) * | 2005-03-22 | 2010-11-16 | Merck Sharp & Dohme Corp. | HCV protease substrates |
AR056327A1 (es) * | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
BRPI0612124A2 (pt) * | 2005-06-24 | 2010-10-19 | Genelabs Tech Inc | derivados de heteroarila para o tratamento de viroses |
CA2627247C (en) * | 2005-10-28 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Hepatitis c virus ns2/3 activity assay |
WO2007145894A2 (en) | 2006-06-08 | 2007-12-21 | Merck & Co., Inc. | A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences |
RU2009105837A (ru) * | 2006-07-20 | 2010-08-27 | СмитКлайн Бичем Копэрейшн (US) | Полициклические противовирусные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусной инфекции с ее помощью и названные соединения для изготовления лекарственных средств |
US20100216161A1 (en) * | 2009-02-26 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Method for identifying protease inhibitors |
WO2008112108A1 (en) | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | In vivo hcv resistance to anti-viral inhibitors |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
WO2009029729A1 (en) * | 2007-08-31 | 2009-03-05 | Genelabs Technologies, Inc. | Amino tricyclic-nucleoside compounds, compositions, and methods of use |
AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
EP2595983A1 (en) | 2010-07-22 | 2013-05-29 | Novartis AG | 2,3,5-trisubstituted thiophene compounds and uses thereof |
WO2012092484A2 (en) | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
WO2017025782A1 (en) | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
US10899823B2 (en) | 2018-01-18 | 2021-01-26 | California Institute Of Technology | Programmable protein circuits in living cells |
US11453893B2 (en) | 2018-08-30 | 2022-09-27 | California Institute Of Technology | RNA-based delivery systems with levels of control |
US11542305B2 (en) | 2018-08-31 | 2023-01-03 | California Institute Of Technology | Synthetic protein circuits detecting signal transducer activity |
EP3908653A4 (en) | 2019-01-10 | 2022-11-02 | California Institute of Technology | SYNTHETIC SYSTEM FOR TUNABLE PROTEIN SIGNAL THRESHOLD |
-
1994
- 1994-02-23 IT ITRM940092A patent/IT1272179B/it active IP Right Grant
-
1995
- 1995-02-14 CA CA002182521A patent/CA2182521C/en not_active Expired - Fee Related
- 1995-02-14 JP JP52223995A patent/JP3280384B2/ja not_active Expired - Fee Related
- 1995-02-14 BR BR9506931A patent/BR9506931A/pt not_active Application Discontinuation
- 1995-02-14 EP EP95909937A patent/EP0746333B1/en not_active Expired - Lifetime
- 1995-02-14 US US08/700,356 patent/US5739002A/en not_active Expired - Lifetime
- 1995-02-14 DE DE69509504T patent/DE69509504T2/de not_active Expired - Lifetime
- 1995-02-14 ES ES95909937T patent/ES2132644T3/es not_active Expired - Lifetime
- 1995-02-14 RU RU96119350A patent/RU2149185C1/ru active
- 1995-02-14 WO PCT/IT1995/000018 patent/WO1995022985A1/en active IP Right Grant
- 1995-02-14 AU AU18223/95A patent/AU691259B2/en not_active Ceased
- 1995-02-14 DK DK95909937T patent/DK0746333T3/da active
- 1995-02-14 AT AT95909937T patent/ATE179611T1/de active
-
1998
- 1998-11-13 HK HK98111982A patent/HK1010988A1/xx not_active IP Right Cessation
-
1999
- 1999-05-07 GR GR990401236T patent/GR3030166T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE179611T1 (de) | 1999-05-15 |
ITRM940092A0 (it) | 1994-02-23 |
IT1272179B (it) | 1997-06-16 |
JP3280384B2 (ja) | 2002-05-13 |
AU1822395A (en) | 1995-09-11 |
DE69509504D1 (de) | 1999-06-10 |
US5739002A (en) | 1998-04-14 |
WO1995022985A1 (en) | 1995-08-31 |
HK1010988A1 (en) | 1999-07-02 |
GR3030166T3 (en) | 1999-08-31 |
EP0746333B1 (en) | 1999-05-06 |
DK0746333T3 (da) | 1999-11-01 |
BR9506931A (pt) | 1997-09-09 |
AU691259B2 (en) | 1998-05-14 |
RU2149185C1 (ru) | 2000-05-20 |
ITRM940092A1 (it) | 1995-08-23 |
DE69509504T2 (de) | 1999-09-02 |
EP0746333A1 (en) | 1996-12-11 |
CA2182521C (en) | 1999-07-06 |
JPH10500005A (ja) | 1998-01-06 |
CA2182521A1 (en) | 1995-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2132644T3 (es) | Metodo para reproducir in vitro la actividad proteolitica de la proteasa ns3 del virus de la hepatitis c (vhc). | |
ES2196348T3 (es) | Composiciones para retardar el crecimiento del cabello y el uso correspondiente. | |
DE69729786D1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
NO951724L (no) | Frysetörket proteinblanding, samt analysesett | |
ATE500323T1 (de) | Subtilisin-variante | |
ATE212037T1 (de) | Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus | |
RU96119350A (ru) | Способ репродукции in vitro протеолитической активности ns3 протеазы вируса гепатита c(нсу) | |
PT758248E (pt) | Formulacoes para o factor ix | |
FI965225A (fi) | Uusia peptidejä | |
HUP0000908A2 (hu) | Fibrinogén tartalmú stabilizált keverék | |
AR010062A1 (es) | Nuevos benzamidaldehidos y su utilizacion | |
PT1118619E (pt) | Metodo para identificar agentes activos contra o vhc utilizando as coordenadas estruturais da protease do virus da hepatite c | |
DE69736777D1 (de) | Amidinohydrazone als protease-inhibitoren | |
AU1871301A (en) | Serine protease inhibitors | |
TR200003377T2 (tr) | Estrojenler ile bütünleşik 2-fenil-1-[4-(2-aminoetoksi)benzil]-indol | |
AU2220702A (en) | Serine protease inhibitors | |
DE69333954D1 (de) | An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung | |
EP1802778A4 (en) | HCV MULTIPLE EPITOPE FUSION ANTIGENS HAVING MODIFIED PROTEOLYTIC CLEAVAGE SITES AND USES THEREOF | |
TW270145B (en) | Azeotropes of octamethyltrisiloxane and n-propoxypropanol | |
DK0906272T3 (da) | Peptider | |
BR9713176A (pt) | Benzotiofenos amorfos,métodos de preparação e métodos de uso | |
BR0110902A (pt) | Inibidores de mmp-9/mmp-2 | |
ATE305612T1 (de) | Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität | |
AU5069800A (en) | Novel gbv sequence | |
AU4269401A (en) | HCV NS2/3 fragments and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 746333 Country of ref document: ES |